Navigation Links
MacroChem Appoints David P. Luci as New CFO
Date:3/19/2008

WELLESLEY HILLS, Mass., March 19 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced the appointment of David P. Luci to the position of Chief Financial Officer, effective immediately. Mr. Luci has served as MacroChem's General Counsel and Vice President, Corporate Development since joining the Company in December 2007.

Mr. Luci was formerly the CFO of Bioenvision, Inc. prior to its successful merger transaction with Genzyme Corporation valued at $345 mm, and has over 16 years of experience servicing or working in the finance, accounting and legal functions within the healthcare industry. Bioenvision's primary focus was developing compounds for the treatment of cancer. While Mr. Luci was at Bioenvision, the company raised over $100 million of capital through equity financings, primarily lead by UBS and JP Morgan, and developed and successfully obtained regulatory approval for a compound to treat pediatric acute leukemia in end-stage patients.

Mr. Luci is also a member of the board of directors, audit committee chairman and compensation committee chairman of Access Pharmaceuticals (OTC Bulletin Board: ACCP.OB) of Dallas, Texas, a biopharmaceutical company focused on development of novel therapies for cancer and other indications. Prior to Bioenvision he also served as a senior associate in the corporate department of Paul, Hastings, Janofsky & Walker LLP (New York Office) and senior auditor at Ernst & Young, LLP (New York Office). In 1991, Mr. Luci earned certification in public accounting.

Mr. Luci stated. "Since joining the company, I have been further encouraged by our potential for future success and look forward to working in this expanded role through the coming stages of growth and opportunity for the Company."

Bernard Patriacca, MacroChem's Chief Financial Officer, will be retiring as planned following the filing of the company's annual report for the year ended December 31, 2007 which occurred on Monday, March 17, 2008. Mr. Robert DeLuccia, President and CEO of MacroChem, stated, "On behalf of our Board of Directors and the Company, we sincerely thank Mr. Patriacca for his substantial contributions to our operations over the past seven years and offer our very best wishes in his retirement. Mr. Patriacca will remain a consultant to the Company to ensure a smooth transition." He continued, "We are very pleased to have someone with David's experience and skill contributing to our ongoing development activities in his expanded capacity."

He added, "Mr. Luci brings a diverse legal, financial, and business background as well as excellent knowledge of the biotech sector, both with pharmaceutical companies and the investment community of our industry. His experience includes capital markets financing, negotiating deals, and license agreements (both U.S. and ex-U.S.), corporate partnerships, and mergers and acquisitions. I believe this impressive skill set will serve us well as we seek to capitalize on our recent achievements and advance MacroChem's initiatives in the coming year."

Mr. Luci received his JD, cum laude, from Albany Law School of Union University, and his Bachelor of Science in Business Administration from Bucknell University. He is a member of the New York Bar Association and a Certified Public Accountant (Pennsylvania).

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidates are EcoNail(R) and pexiganan. EcoNail is a topically applied SEPA- based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates includes products based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:

Dave Luci, CFO and VP Corporate Development

(781) 489-7310

dluci@macrochem.com


'/>"/>
SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
2. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
3. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
4. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
5. RainDance Appoints Becker Chief Commercial Officer
6. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
7. iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs
8. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
9. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
10. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
11. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs has ... Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables ... for further growth in 2017. Extractable & Leachable evaluations have become increasingly more ...
(Date:1/18/2017)... ... 2017 , ... BidMed, LLC, announced it will hold a 1-day ... equipment from two different leading institutes. This highly specialized laboratory equipment is coming directly ... This 1-day online auction will take place on BidMed’s website http://www.bidmed.com ...
(Date:1/18/2017)... Texas , Jan. 18, 2017  Caris ... and the Lustgarten Foundation, the largest private funder ... a clinical trial evaluating the impact of immunotherapy ... providing clinical trial enrollment services to identify potential ... facilitate communication between treating physicians and study investigators. ...
Breaking Biology Technology:
(Date:12/8/2016)... Market Research Future published a half cooked research report ... Security and Service Market is expected to grow over the CAGR ... Highlights: ... Mobile Biometric Security and Service Market is ... of authentication and security from unwanted cyber threats. The increasing use ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):